Seyi Samson Enitan
1* 
, Princess Hephzibah Soboyejo
1 , Kester Awharentomah Digban
2 , Michael Unata Iduh
3 , Ifeoluwapo Oyebola Asekun-Olarinmoye
4 , Chidimma Anthonia Azike
5 , Grace Eleojo Itodo
6 , Ameh Raphael Adole
7 , Ayomide Oluwatobiloba Okuneye
1 1 Department of Medical Laboratory Science, School of Public and Allied Health, Babcock University, Ilishan-Remo 121109, Ogun State, Nigeria
2 Department of Medical Laboratory Science, College of Medical & Health Sciences, Novena University, Ogume, Kwale 322107, Delta State, Nigeria
3 Department of Medical Microbiology, School of Medical Laboratory Science, Usmanu Danfodiyo University, Sokoto, Sokoto State Nigeria
4 Faculty of Basic Medical Sciences, University of Ilesa, Ilesa, Osun State, Nigeria
5 Department of Medical Laboratory Science, Faculty of Medical Laboratory Science, Rivers State University, Eagle Island, Port Harcourt 500101, Rivers State, Nigeria
6 Department of Microbiology, Federal Teaching Hospital, Lokoja, Kogi State, Nigeria
7 Department of Infectious disease, Clinton Health Access Initiative, FCT-Abuja, Nigeria
Abstract
Recent advancements in the treatment of hepatitis C virus (HCV) infection have significantly advanced the goal of achieving a hepatitis C-free world. The introduction of direct-acting antivirals (DAAs) has revolutionized treatment, offering over 95% cure rates, shorter treatment durations, and fewer side effects. Pan-genotypic regimens, such as sofosbuvir/velpatasvir, have further simplified treatment by being effective across all HCV genotypes. Despite these advancements, substantial challenges persist globally. An estimated 50 million people are living with chronic HCV worldwide, yet many remain undiagnosed, particularly in low- and middle-income countries, where there is limited healthcare infrastructure. High treatment costs further restrict access to these life-saving therapies. Reinfection rates remain high among certain populations, such as people who inject drugs (PWIDs), and stigma continues to deter individuals from seeking testing and treatment. To advance HCV elimination, future efforts must prioritize universal screening, affordable treatment, improved diagnostic technologies, and intensified research into vaccine development. Strengthened global and local collaboration is essential to overcome these challenges and reduce the global HCV burden.